Vicapsys Life Sciences annual stock-based compensation
2019
2020
2021
2022
2023
Vicapsys Life Sciences Stock-Based Compensation Growth & History (VICP)
Vicapsys Life Sciences's stock-based compensation was $20,697 for fiscal 2023.
View full Vicapsys Life Sciences company overviewVicapsys Life Sciences annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2023 | 2023-12-31 | $20,697 | −$84,953 | −80.41% |
| 2022 | 2022-12-31 | $105,650 | $101,324 | +2342.21% |
| 2021 | 2021-12-31 | $4,326 | −$10,455 | −70.73% |
| 2020 | 2020-12-31 | $14,781 | −$103,868 | −87.54% |
| 2019 | 2019-12-31 | $118,649 | — | — |
Vicapsys Life Sciences quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q4 2023 | 2023-12-31 | $0 | −$62,093 | — |
| Q3 2023 | 2023-09-30 | $0 | −$41,395 | — |
| Q2 2023 | 2023-06-30 | $0 | −$1,081 | — |
| Q1 2023 | 2023-03-31 | $20,697 | $19,616 | +1814.62% |
| Q4 2022 | 2022-12-31 | $62,093 | $61,011 | +5638.72% |
| Q3 2022 | 2022-09-30 | $41,395 | $40,314 | +3729.32% |
| Q2 2022 | 2022-06-30 | $1,081 | $0 | 0.00% |
| Q1 2022 | 2022-03-31 | $1,081 | −$1 | −0.09% |
| Q4 2021 | 2021-12-31 | $1,082 | $0 | 0.00% |
| Q3 2021 | 2021-09-30 | $1,081 | −$1,802 | −62.50% |
| Q2 2021 | 2021-06-30 | $1,081 | −$4,327 | −80.01% |
| Q1 2021 | 2021-03-31 | $1,082 | −$4,326 | −79.99% |
| Q4 2020 | 2020-12-31 | $1,082 | — | — |
| Q3 2020 | 2020-09-30 | $2,883 | — | — |
| Q2 2020 | 2020-06-30 | $5,408 | — | — |
| Q1 2020 | 2020-03-31 | $5,408 | — | — |
Vicapsys Life Sciences stock-based compensation trends
Between the periods ended 2019-12-31 and 2023-12-31, Vicapsys Life Sciences's stock-based compensation decreased from $118,649 to $20,697, a change of −$97,952. The latest reported quarter, Q4 2023, shows $0.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vicapsys Life Sciences source filings ↗